|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|
| Revenue (note 16) | ||
| Cost of sales | ||
| Gross profit | ||
| Expenses (note 17) | ||
| Selling and administrative expenses | ||
| Research and development expenses | ||
| Stock-based compensation (note 12) | ||
| Gain on revaluation of options (note 11) | ||
| Gain on revaluation of RSUs (note 11) | ||
| Gain on revaluation of the derivative warrant liability (note 10) | ||
| Foreign exchange loss (gain) (note 22) | ||
| Depreciation (notes 7, 19) | ||
| Amortization (note 8) | ||
| Operating expense excluding cost of sales | ||
| Loss before undernoted items | ||
| Interest expense (note 9) | ||
| Accretion and other financing costs (note 9) | ||
| Loss (gain) on contingent consideration (note 4) | ||
| Impairment of property and equipment (note 7) | ||
| Restructuring costs | ||
| Business acquisition costs | ||
| Other income | ||
| Profit (loss) before tax | ||
| Total expenses | ||
| Current income tax (recovery) expense (note 21) | ||
| Deferred income tax (recovery) expense (note 21) | ||
| Income tax (recovery) expense (note 21) | ||
| Net loss for the year | ||
| Exchange gain (loss) on translating foreign operations | ||
| Comprehensive loss for the year | ||
| Net loss per share (note 13) | ||
| Basic | ||
| Diluted | ||
| Weighted average number of common shares outstanding - basic (note 13) | ||
| Weighted average number of common shares outstanding - diluted (note 13) |
Loading...
